Document is current
Any future updates will be listed below
-
Authors
Lopez de Rodas, Miguel https://orcid.org/0000-0002-6062-4064
Villalba-Esparza, Maria https://orcid.org/0000-0002-9183-0610
Sanmamed, Miguel F.
Chen, Lieping
Rimm, David L. https://orcid.org/0000-0001-5820-4397
Schalper, Kurt A. https://orcid.org/0000-0001-5692-4833
- License Information
-
More Information
Article History
Accepted: 19 December 2024
First Online: 16 January 2025
Competing interests
: M.F.S. had received fees for consultancy from Bristol Myers Squibb, MSD, Numab and Roche; and his laboratory has received funding from Bristol Myers Squibb and Roche. L.C. has been a consultant for NextCure, OncoC4, Tcelltech and Zai Lab; is a scientific founder of DynamiCure, NextCure, Normunity and Tcelltech; and his laboratory has received funding from DynamiCure, NextCure and Normunity. D.L.R. has served as an adviser for Agendia, Amgen, AstraZeneca, Bristol Myers Squibb, Cell Signalling Technology, Cepheid, Danaher, Daiichi Sankyo, Genoptix/Novartis, GSK, Halda Biotherapeutics, Incendia, Konica Minolta, Merck, NanoString, PAIGE.AI, Perkin Elmer, Roche, Sanofi and Ventana; and his laboratory has received funding from Amgen, Cepheid, Navigate Biopharma, NextCure, Leica and Konica Minolta. K.A.S. has served as a consultant, adviser or speaker for Agenus, AstraZeneca, Bristol Myers Squibb, Clinica Alemana Santiago, CSRlife, Dynamicure, EMD Serono, Forefront Collaborative, Genmab, Indaptus, Merck, Merus, Moderna, Molecular Templates, OnCusp, Parthenon Therapeutics, PeerView, Physicians Education Resource, Roche, Sanofi, Shattuck Labs, Takeda and Torque/Repertoire Therapeutics; and his laboratory has received research funding from Akoya Biosciences, AstraZeneca, Boehringer-Ingelheim, Bristol Myers Squibb, Eli Lilly, Merck, NextPoint Therapeutics, Ribon Therapeutics, Roche, Surface Oncology, Takeda and Tesaro/GSK. M.L.d.R. and M.V.-E. declare no competing interests.
